Nomura: Maintains a "buy" rating on SINOPHARM (01099) and lowers the target price to 25.09 Hong Kong dollars.
According to the estimate, the revenue of the company in the last quarter is expected to decrease by 0.4% year-on-year, while the profit is expected to drop by 2.8%.
Nomura released a research report stating that they maintain a "buy" rating for SINOPHARM (01099) with a target price lowered from 28.46 Hong Kong dollars to 25.09 Hong Kong dollars. The bank has lowered the group's sales forecast for 2024 and 2025 by 1.4% each, and reduced profit forecasts by 5.3% each to reflect profit pressure and credit losses or impairments. The bank estimates that Sinopharm's revenue in the last quarter will decrease by 0.4% year-on-year, while profits will drop by 2.8%.
Related Articles
AAC TECH spent HKD 9.96 million to repurchase 300,000 shares on March 31st.
Tencent (00700) spent HKD 301 million on repurchasing 621,000 shares on March 31st.
HUARONG ENERGY(01101): Delayed announcement of 2025 annual performance
AAC TECH spent HKD 9.96 million to repurchase 300,000 shares on March 31st.
Tencent (00700) spent HKD 301 million on repurchasing 621,000 shares on March 31st.
HUARONG ENERGY(01101): Delayed announcement of 2025 annual performance
RECOMMEND
Chinese Innovative Drug Assets Attract Major Foreign Acquisition, Cooperation Models Diversify
26/03/2026
Four Giants Subscribe As Memory Manufacturer Confirms TWD 78.718 Billion Private Placement For Capacity Expansion
26/03/2026
Year‑On‑Year Surge Exceeding 500%: Hong Kong IPOs Top HKD 100 Billion This Year
26/03/2026
